Hot Search:

NOD/ShiLtJGpt-Prkdcem26Cd52Il2rgem26Cd22/Gpt

NCG|Strain NO.T001475

Knockout (KO)

  • Product Type:
  • Quantity: - +
  • Sex:
  • Age:
  • Genotype:
BASIC INFORMATION
Strain Name: NOD/ShiLtJGpt-Prkdcem26Cd52Il2rgem26Cd22/Gpt
Strain Number: T001475
Official Symbol: Prkdc,Il2rg
Strain Strategy: T001475.NCG strain info.pdf
Official Full Name: protein kinase DNA activated catalytic polypeptide,interleukin 2 receptor gamma chain
Also Known As: AI326420,AU019811,DNA-PKcs,DNAPDcs,DNAPK,DNPK1,DOXNPH,HYRC1,XRCC7,dxnph,p460
NCBI Number: 1909016186
MGI Number: 10477996551
Research Areas: Humanized model,Humanization of the immune system,Immunodeficiency
Strain Background: [N000235] NOD/ShiLtJGpt
Modification Type: Knockout (KO)
Inventory Status: Live,Cryopreserved
Sale Status: IF (Available for Distribution)
Health Status: Specific pathogen free (SPF)
Health Report: Please log in to view
Publications: 1. Blockade of dual immune checkpoint inhibitory signals with a CD47/PD-L1 bispecific antibody for cancer treatment. Theranostics (2023)2. Cytoplasmic NEAT1 Suppresses AML Stem Cell Self‐Renewal and Leukemogenesis through Inactivation of Wnt Signaling. Advanced Science (2021)3. Loss of PRMT7 reprograms glycine metabolism to selectively eradicate leukemia stem cells in CML. Cell Metab (2022)4. Biomimetic Nanoerythrosome‐Coated Aptamer‐DNA Tetrahedron/Maytansine Conjugates: pH‐Responsive and Targeted Cytotoxicity for HER2‐positive Breast Cancer. Advanced Materials (2022)5. Interferon-a potentiates anti-PD-1 efficacy by remodeling glucose metabolism in the hepatocellular carcinoma microenvironment. Cancer discovery (2022)6. Autologous transplantation of thecal stem cells restores ovarian function in nonhuman primates. Cell Discovery (2021)7. ACSS3 represses prostate cancer progression through downregulating lipid droplet-associated protein PLIN3. Theranostics (2021)8. Melatonin inhibits lipid accumulation to repress prostate cancer progression by mediating the epigenetic modification of CES1. Clinical and translational medicine (2021)9. Pericytes augment glioblastoma cell resistance to temozolomide through CCL5-CCR5 paracrine signaling. Cell research (2021)10. Creatine promotes cancer metastasis through activation of Smad2/3. Cell metabolism (2021)11. Rapamycin pretreatment rescues the bone marrow AML cell elimination capacity of CAR-T cells. Clinical Cancer Research (2021)12. AAV-mediated in vivo CAR gene therapy for targeting human T-cell leukemia. Blood Cancer Journal (2021)13. Chimeric STAR receptors using TCR machinery mediate robust responses against solid tumors. Science Translational Medicine (2021)14. Development of an antibody-like T-cell engager based on VH-VL heterodimer formation and its application in cancer therapy. Biomaterials (2021)15. The Rational Development of CD5-targeting Biepitopic Chimeric Antigen Receptors with Fully Human Heavy-chain-only Antigen Recognition Domains. Molecular Therapy (2021)16. N7-Methylguanosine tRNA modification enhances oncogenic mRNA translation and promotes intrahepatic cholangiocarcinoma progression. Molecular Cell (2021)17. Tandem CAR-T cells targeting CD70 and B7-H3 exhibit potent preclinical activity against multiple solid tumors. Theranostics (2020)18. ARID1A hypermethylation disrupts transcriptional homeostasis to promote squamous cell carcinoma progression. Cancer research (2020)19. ARID1A prevents squamous cell carcinoma initiation and chemoresistance by antagonizing pRb/E2F1/c-Myc-mediated cancer stemness. Cell Death & Differentiation (2020)20. Combination of metabolic intervention and T cell therapy enhances solid tumor immunotherapy. Science Translational Medicine (2020)21. Dendrimer-Functionalized Superparamagnetic Nanobeacons for Real-Time Detection and Depletion of HSP90α mRNA and MR Imaging. Theranostics (2019)22. Genetically modified CD7-targeting allogeneic CAR-T cell therapy with enhanced efficacy for relapsed/refractory CD7-positive hematological malignancies: a phase I clinical study. Cell Res (2022)23. OXTR(High) stroma fibroblasts control the invasion pattern of oral squamous cell carcinoma via ERK5 signaling. Nat Commun (2022)24. Non-viral, specifically targeted CAR-T cells achieve high safety and efficacy in B-NHL. Nature (2022)25. Acquired semi-squamatization during chemotherapy suggests differentiation as a therapeutic strategy for bladder cancer. Cancer Cell (2022)26. Cancer-associated fibroblast-specific lncRNA LINC01614 enhances glutamine uptake in lung adenocarcinoma. J Hematol Oncol (2022)27. Identification of novel HLA-A*11:01-restricted HPV16 E6/E7 epitopes and T-cell receptors for HPV-related cancer immunotherapy. J Immunother Cancer (2022)28. Targeting ARF1-IQGAP1 interaction to suppress colorectal cancer metastasis and vemurafenib resistance. J Adv Res (2022)29. Hook&Loop multivalent interactions based on disk-shaped nanoparticles strengthen active targeting. J Control Release (2023)30. Downregulation of phosphoserine phosphatase potentiates tumor immune environments to enhance immune checkpoint blockade therapy. Journal for ImmunoTherapy of Cancer (2023)31. BPA‐Containing Polydopamine Nanoparticles for Boron Neutron Capture Therapy in a U87 Glioma Orthotopic Model. Advanced Functional Materials (2023)32. Anti-BCMA surface engineered biomimetic photothermal nanomissile enhances multiple myeloma cell apoptosis and overcomes the disturbance of NF-kappaB signaling in vivo. Biomaterials (2023)33. EHBP1L1 Drives Immune Evasion in Renal Cell Carcinoma through Binding and Stabilizing JAK1. Adv Sci (2023)34. Expansion of human megakaryocyte-biased hematopoietic stem cells by biomimetic Microniche. Nat Commun (2023)35. Supramolecular nanofibers co-loaded with dabrafenib and doxorubicin for targeted and synergistic therapy of differentiated thyroid carcinoma. Theranostics (2023)36. PD-L1 methylation restricts PD-L1/PD-1 interactions to control cancer immune surveillance. SCI ADV (2023)37. Impaired histone inheritance promotes tumor progression. Nat Commun (2023)38. NOTCH4(DeltaL12_16) sensitizes lung adenocarcinomas to EGFR-TKIs through transcriptional down-regulation of HES1. Nat Commun (2023)39. Targeting Trop2 by Bruceine D suppresses breast cancer metastasis by blocking Trop2/beta-catenin positive feedback loop. J Adv Res (2023)40. GAS6-based CAR-T cells exhibit potent antitumor activity against pancreatic cancer. J Hematol Oncol (2023)41. Lenvatinib improves anti-PD-1 therapeutic efficacy by promoting vascular normalization via the NRP-1-PDGFRbeta complex in hepatocellular carcinoma. Front Immunol (2023)42. Nanobody-derived bispecific CAR-T cell therapy enhances the anti-tumor efficacy of T cell lymphoma treatment. Mol Ther Oncolytics (2023)43. Preconditioning of radiotherapy enhances efficacy of B7-H3-CAR-T in treating solid tumor models. Life Sci (2023)44. Targeted delivery of a PD-1-blocking scFv by CD133-specific CAR-T cells using nonviral Sleeping Beauty transposition shows enhanced antitumour efficacy for advanced hepatocellular carcinoma. BMC Med (2023)45. Targeting Bcl-xL is a potential therapeutic strategy for extranodal NK/T cell lymphoma. iScience (2023)46. Treating solid tumors with TCR-based chimeric antigen receptor targeting extra domain B-containing fibronectin. J Immunother Cancer (2023)47. WDR54 exerts oncogenic roles in T-cell acute lymphoblastic leukemia. Cancer Sci (2023)48. Activation of melanocortin-1 receptor signaling in melanoma cells impairs T cell infiltration to dampen antitumor immunity. Nat Commun (2023)49. Downregulation of RCN1 promotes pyroptosis in acute myeloid leukemia cells. Mol Oncol (2023)50. The application of HER2 and CD47 CAR-macrophage in ovarian cancer. J Transl Med (2023)51. A drug-delivery depot for epigenetic modulation and enhanced cancer immunotherapy. Biomed Pharmacother (2023)52. A human mucosal melanoma organoid platform for modeling tumor heterogeneity and exploring immunotherapy combination options. Sci Adv (2023)53. Intratumoral CD103(+) CD8(+) T cells predict response to neoadjuvant chemoimmunotherapy in advanced head and neck squamous cell carcinoma. Cancer Commun (2023)54. Novel mesothelin-targeted chimeric antigen receptor-modified UNKT cells are highly effective in inhibiting tumor progression. Pharmacol Res (2023)55. The liver microenvironment orchestrates FGL1-mediated immune escape and progression of metastatic colorectal cancer. Nat Commun (2023)56. Enhancement of the viability of T cells electroporated with DNA via osmotic dampening of the DNA-sensing cGAS-STING pathway. Nat Biomed Eng (2023)57. Lipid accumulation-mediated histone hypoacetylation drives persistent NK cell dysfunction in anti-tumor immunity. Cell Rep (2023)58. Cell surface GRP78-directed CAR-T cells are effective at treating human pancreatic cancer in preclinical models. Transl Oncol (2024)59. GARP-mediated active TGF-beta1 induces bone marrow NK cell dysfunction in AML patients with early relapse post-allo-HSCT. Blood (2022)60. Long noncoding RNA NONHSAT160169.1 promotes resistance via hsa-let-7c-3p/SOX2 axis in gastric cancer. Sci Rep (2023)61. Repression of LSD1 potentiates homologous recombination-proficient ovarian cancer to PARP inhibitors through down-regulation of BRCA1/2 and RAD51. Nat Commun (2023)62. Tumor-infiltrating platelets promote the growth of lung adenocarcinoma. Translational Oncology (2024)63. Carboxypeptidase A4 negatively regulates HGS-ETR1/2-induced pyroptosis by forming a positive feedback loop with the AKT signalling pathway. Cell Death Dis (2023)64. Personalized drug screening in patient-derived organoids of biliary tract cancer and its clinical application. Cell Rep Med (2023)65. Targeting gut microbial nitrogen recycling and cellular uptake of ammonium to improve bortezomib resistance in multiple myeloma. Cell Metab (2024)66. Hepatitis B Virus-Encoded MicroRNA (HBV-miR-3) Inhibits FIH-1 Expression to Promote Tumor Angiogenesis in HBV-Related Hepatocellular Carcinoma. J Hepatocell Carcinoma (2023)67. A Near-Infrared-II Fluorescent Nanocatalyst for Enhanced CAR T Cell Therapy against Solid Tumor by Immune Reprogramming. ACS Nano (2023)68. Sufficiently activated mature natural killer cells derived from peripheral blood mononuclear cells substantially enhance antitumor activity. Immun Inflamm Dis (2024)69. IL-21-armored B7H3 CAR-iNKT cells exert potent antitumor effects. iScience (2024)70. FKBP10 promotes clear cell renal cell carcinoma progression and regulates sensitivity to the HIF2alpha blockade by facilitating LDHA phosphorylation. Cell Death Dis (2024)71. Enhanced Precision Therapy of Multiple Myeloma Through Engineered Biomimetic Nanoparticles with Dual Targeting. Engineering (2024)72. Cell-Surface GRP78-Targeted Chimeric Antigen Receptor T Cells Eliminate Lung Cancer Tumor Xenografts. Int J Mol Sci (2024)73. An Anti-CD7 Antibody-Drug Conjugate Target Showing Potent Antitumor Activity for T-Lymphoblastic Leukemia (T-ALL). Biomolecules (2024)74. Effects of methionine deficiency on B7H3-DAP12-CAR-T cells in the treatment of lung squamous cell carcinoma. Cell Death Dis (2024)75. Endoplasmic reticulum aminopeptidase 2 regulates CD4(+) T cells pyroptosis in rheumatoid arthritis. ARTHRITIS RESEARCH & THERAPY (2024)76. RNA-binding protein RBM5 plays an essential role in acute myeloid leukemia by activating the oncogenic protein HOXA9. Genome Biol (2024)77. A trispecific antibody induces potent tumor-directed T-cell activation and antitumor activity by CD3/CD28 co-engagement. Immunotherapy (2024)78. MTHFD1 regulates the NADPH redox homeostasis in MYCN-amplified neuroblastoma. Cell Death Dis (2024)79. RORalpha is required for expansion and memory maintenance of ILC1s via a lymph node-liver axis. Cell Rep (2024)80. High-fat diet promotes prostate cancer metastasis via RPS27. Cancer & Metabolism (2024)81. CYP2E1-dependent upregulation of SIRT7 is response to alcohol mediated metastasis in hepatocellular carcinoma. Cancer Gene Ther (2022)82. The construction of modular universal chimeric antigen receptor T (MU-CAR-T) cells by covalent linkage of allogeneic T cells and various antibody fragments. Mol Cancer (2024)83. RBP7 functions as a tumor suppressor in HR + breast cancer by inhibiting the AKT/SREBP1 pathway and reducing fatty acid. Cancer Cell Int (2024)84. Inhibition of SFTSV replication in humanized mice by a subcutaneously administered anti-PD1 nanobody. EMBO Mol Med (2024)85. Co-targeting CD47 and VEGF elicited potent anti-tumor effects in gastric cancer. Cancer Immunol Immunother (2024)86. Bispecific CAR T cell therapy targeting BCMA and CD19 in relapsed/refractory multiple myeloma: a phase I/II trial. Nat Commun (2024)87. Development of nanobodies targeting hepatocellular carcinoma and application of nanobody-based CAR-T technology. J Transl Med (2024)88. DR30318, a novel tri-specific T cell engager for Claudin 18.2 positive cancers immunotherapy. Cancer Immunol Immunother (2024)89. GATA3 functions downstream of BRCA1 to promote DNA damage repair and suppress dedifferentiation in breast cancer. BMC Biol (2024)90. ISG12a promotes immunotherapy of HBV-associated hepatocellular carcinoma through blocking TRIM21/AKT/beta-catenin/PD-L1 axis. iScience (2024)91. m(6)A-dependent upregulation of DDX21 by super-enhancer-driven IGF2BP2 and IGF2BP3 facilitates progression of acute myeloid leukaemia. Clin Transl Med (2024)92. PTPLAD1 Regulates PHB-Raf Interaction to Orchestrate Epithelial-Mesenchymal and Mitofusion-Fission Transitions in Colorectal Cancer. Int J Biol Sci (2024)93. PD-1 downregulation enhances CAR-T cell antitumor efficiency by preserving a cell memory phenotype and reducing exhaustion. J Immunother Cancer (2024)94. Self-Assembled Multivalent Aptamer Drug Conjugates: Enhanced Targeting and Cytotoxicity for HER2-Positive Gastric Cancer. ACS Appl Mater Interfaces (2023)95. STING agonist diABZI enhances the cytotoxicity of T cell towards cancer cells. Cell Death Dis (2024)96. Cancer-associated fibroblasts derived fibronectin extra domain A promotes sorafenib resistance in hepatocellular carcinoma cells by activating SHMT1. Genes & Diseases (2024)97. CXCL10 and IL15 co-expressing chimeric antigen receptor T cells enhance anti-tumor effects in gastric cancer by increasing cytotoxic effector cell accumulation and survival. Oncoimmunology (2024)98. Elesclomol-copper synergizes with imidazole ketone erastin by promoting cuproptosis and ferroptosis in myelodysplastic syndromes. Biomed Pharmacother (2024)99. Discovery of the Clinical Candidate Sonrotoclax (BGB-11417), a Highly Potent and Selective Inhibitor for Both WT and G101V Mutant Bcl-2. J Med Chem (2024)100. Expand available targets for CAR-T therapy to overcome tumor drug resistance based on the "Evolutionary Traps". Pharmacol Res (2024)101. NCX1/Ca(2+) promotes autophagy and decreases bortezomib activity in multiple myeloma through non-canonical NFkappaB signaling pathway. Cell Commun Signal (2024)102. Priming with LSD1 inhibitors promotes the persistence and antitumor effect of adoptively transferred T cells. Nat Commun (2024)103. Targeted degradation of oncogenic BCR-ABL by silencing the gene of NEDD8 E3 ligase RAPSYN. J Nanobiotechnology (2024)104. Zebularine potentiates anti-tumor immunity by inducing tumor immunogenicity and improving antigen processing through cGAS-STING pathway. Commun Biol (2024)105. An herbal formula Shenlian decoction upregulates M1/M2 macrophage proportion in hepatocellular carcinoma by suppressing complement cascade. Biomed Pharmacother (2024)106. EBV promotes TCR-T-cell therapy resistance by inducing CD163+M2 macrophage polarization and MMP9 secretion. J Immunother Cancer (2024)107. Liensinine diperchlorate and artemisitene synergistically attenuate breast cancer progression through suppressing PI3K-AKT signaling and their efficiency in breast cancer patient-derived organoids. Biomed Pharmacother (2024)108. Preclinical evaluation of cyclophosphamide and fludarabine combined with CD19 CAR-T in the treatment of B-cell hematologic malignancies in vivo. Oncol Res (2024)109. A full-length glycoprotein mRNA vaccine confers complete protection against severe fever with thrombocytopenia syndrome virus, with broad-spectrum protective effects against ban. Journal of Virology (2024)110. A distinct subset of urothelial cells with enhanced EMT features promotes chemotherapy resistance and cancer recurrence by increasing COL4A1-ITGB1 mediated angiogenesis. Drug Resist Updat (2024)111. A general pHLA-CD80 scaffold fusion protein to promote efficient antigen-specific T cell-based immunotherapy. Mol Ther Oncol (2024)112. Further evidence from DNAH12 supports favorable fertility outcomes of infertile males with dynein axonemal heavy chain gene family variants. iScience (2024)113. N(6)-methyladenosine modification of circMARK2 enhances cytoplasmic export and stabilizes LIN28B, contributing to the progression of Wilms tumor. J Exp Clin Cancer Res (2024)114. Off-the-shelf CAR-NK cells targeting immunogenic cell death marker ERp57 execute robust antitumor activity and have a synergistic effect with ICD inducer oxaliplatin. J Immunother Cancer (2024)115. Pancreatic STAT5 activation promotes Kras(G12D)-induced and inflammation-induced acinar-to-ductal metaplasia and pancreatic cancer. Gut (2024)116. RSL3 enhances ROS-mediated cell apoptosis of myelodysplastic syndrome cells through MYB/Bcl-2 signaling pathway. Cell Death Dis (2024)117. ATP6V0A1-dependent cholesterol absorption in colorectal cancer cells triggers immunosuppressive signaling to inactivate memory CD8(+) T cells. Nat Commun (2024)118. An oncolytic virus delivering tumor-irrelevant bystander T cell epitopes induces anti-tumor immunity and potentiates cancer immunotherapy. Nat Cancer (2024)119. PIM1/NF-kappaB/CCL2 blockade enhances anti-PD-1 therapy response by modulating macrophage infiltration and polarization in tumor microenvironment of NSCLC. Oncogene (2024)120. Tumor-intrinsic P2RY6 drives immunosuppression by enhancing PGE(2) production. Cell Rep (2024)121. Apatinib remodels the immunosuppressive tumor ecosystem of gastric cancer enhancing anti-PD-1 immunotherapy. Cell Rep (2023)122. COLEC10 inhibits the stemness of hepatocellular carcinoma by suppressing the activity of beta-catenin signaling. Cellular Oncology (2024)123. LIM domain only 7: a novel driver of immune evasion through regulatory T cell differentiation and chemotaxis in pancreatic ductal adenocarcinoma. Cell Death Differ (2024)124. Concomitant targeting of FLT3 and SPHK1 exerts synergistic cytotoxicity in FLT3-ITD(+) acute myeloid leukemia by inhibiting beta-catenin activity via the PP2A-GSK3beta axis. Cell Commun Signal (2024)125. ALKBH5 governs human endoderm fate by regulating the DKK1/4-mediated Wnt/beta-catenin activation. Nucleic Acids Res (2024)126. Mito-LND and (E)-Akt inhibitor-IV: novel compounds inducing endoplasmic reticulum stress and ROS accumulation against hepatocellular carcinoma. J Transl Med (2024)127. PDCD4 interacting with PIK3CB and CTSZ promotes the apoptosis of multiple myeloma cells. FASEB J (2024)128. Development of a Novel Peptide-Based PET Tracer [(68)Ga]Ga-DOTA-BP1 for BCMA Detection in Multiple Myeloma. J Med Chem (2024)129. Dialog between mantle cell lymphoma cells and lymphoma-associated macrophages underlies ibrutinib resistance. J Adv Res (2024)130. Reshaping tumor microenvironment by regulating local cytokines expression with a portable smart blue-light controlled device. Commun Biol (2024)131. CBX2 enhances the progression and TMZ chemoresistance of glioma via EZH2-mediated epigenetic silencing of PTEN expression. Front Pharmacol (2024)132. PKCα inhibitors promote breast cancer immune evasion by maintaining PD-L1 stability. Acta Pharmaceutica Sinica B (2024)133. A novel bispecific T-cell engager using the ligand-target csGRP78 against acute myeloid leukemia. Cell Mol Life Sci (2024)134. Personalized drug screening using patient-derived organoid and its clinical relevance in gastric cancer. Cell Rep Med (2024)135. Single-cell RNA sequencing reveals transcriptomic landscape and potential targets for human testicular ageing.. Human Reproduction (2024)136. ISB 2001 trispecific T cell engager shows strong tumor cytotoxicity and overcomes immune escape mechanisms of multiple myeloma cells. Nature Cancer (2024)137. Aligned fibrous scaffolds promote directional migration of breast cancer cells via caveolin-1/YAP-mediated mechanosensing. Materials Today Bio (2024)138. BTN3A1 expressed in cervical cancer cells promotes Vγ9Vδ2 T cells exhaustion through upregulating transcription factors NR4A2/3 downstream of TCR signaling. Cell Communication and Signaling (2024)139. NL101 synergizes with the BCL-2 inhibitor venetoclax through PI3K-dependent suppression of c-Myc in acute myeloid leukaemia. Journal of Translational Medicine (2024)140. The 8‐oxoguanine DNA glycosylase‐synaptotagmin 7 pathway increases extracellular vesicle release and promotes tumour metastasis during oxidative stress. Journal of Extracellular Vesicles (2024)141. Human intermediate prostate cancer stem cells contribute to the initiation and development of prostate adenocarcinoma. Stem Cell Research & Therapy (2024)142. Single-cell sequencing analysis of multiple myeloma heterogeneity and identification of new theranostic targets. Cell Death & Disease (2024)143. A highly selective PI3Kδ inhibitor BGB-10188 shows superior preclinical anti-tumor activities and decreased on-target side effects on colon. Neoplasia (2024)144. EphA2 specific chimeric antigen receptor engineered T cells for the treatment of prostate cancer. Translational Oncology (2024)145. DB-1314, a novel DLL3-targeting ADC with DNA topoisomerase I inhibitor, exhibits promising safety profile and therapeutic efficacy in preclinical small cell lung cancer models. J Transl Med (2024)146. YAP1 Inhibition Induces Phenotype Switching of Cancer-Associated Fibroblasts to Tumor Suppressive in Prostate Cancer. Cancer Research (2024)147. ACSL6-activated IL-18R1–NF-κB promotes IL-18–mediated tumor immune evasion and tumor progression.. Science Advances (2024)148. Efficacy and safety evaluation of cross-reactive Fibroblast activation protein scFv-based CAR-T cells. Front Immunol (2024)149. Preclinical comparison of prolgolimab, pembrolizumab and nivolumab. Scientific Reports (2024)150. Tertiary lymphoid structure-related score as a predictor for survival prognosis and immunotherapy response in head and neck squamous cell carcinoma. Front Immunol (2024)151. Development of a humanized mouse model with functional human materno-fetal interface immunity. JCI Insight (2024)152. MEK inhibition prevents CAR-T cell exhaustion and differentiation via downregulation of c-Fos and JunB. Signal Transduct Target Ther (2024)153. TRIB3 inhibition by palbociclib sensitizes prostate cancer to ferroptosis via downregulating SOX2/SLC7A11 expression. Cell Death Discov (2024)154. Novel bispecific antibody-drug conjugate targeting PD-L1 and B7-H3 enhances antitumor efficacy and promotes immune-mediated antitumor responses. J Immunother Cancer (2024)155. Antigen-independent activation is critical for the durable antitumor effect of GUCY2C-targeted CAR-T cells. J Immunother Cancer (2024)156. PARP inhibitors enhance antitumor immune responses by triggering pyroptosis via TNF–caspase 8–GSDMD/E axis in ovarian cancer. Journal for Immunotherapy of Cancer (2024)157. Targeting CD5 chimeric antigen receptor-engineered natural killer cells against T-cell malignancies. Exp Hematol Oncol (2024)158. Radiotherapy enhances the anti-tumor effect of CAR-NK cells for hepatocellular carcinoma. J Transl Med (2024)159. HCP5 Derived Novel Microprotein Triggers Progression of Gastric Cancer through Regulating Ferroptosis. Adv Sci (Weinh) (2024)160. GB18-06, a nanobody targeting GDF15, effectively alleviates weight loss and restores physical function in cachexia models. MAbs (2024)161. Targeting KIFC1 Promotes Senescence in Soft Tissue Sarcoma via FXR1‐Dependent Regulation of MAD2L1 mRNA Stability. Adv Sci (Weinh) (2024)162. A Self-Activating IL-15 Chimeric Cytokine Receptor to Empower Cancer Immunotherapy. Immunotargets Ther (2024)163. Systemic delivery of tannic acid-ferric-masked oncolytic adenovirus reprograms tumor microenvironment for improved therapeutic efficacy in glioblastoma. Cancer Gene Ther (2024)164. Thymosin α1 reverses oncolytic adenovirus-induced M2 polarization of macrophages to improve antitumor immunity and therapeutic efficacy. Cell Reports Medicine (2024)165. GG-NER's role in androgen receptor signaling inhibitor response for advanced prostate cancer. Cell Communication and Signaling (2024)166. EBV-induced upregulation of CD55 reduces the efficacy of cetuximab treatment in nasopharyngeal carcinoma. J Transl Med (2024)167. Targeting ROR2 Homooligomerization Disrupts ROR2-dependent Signaling And Suppress Stem-like Cell Properties Of Human Breast Adenocarcinoma. iScience (2024)168. SEMA3G-NRP1 Signaling Functions as an Immune Checkpoint that Enables Tumor Immune Evasion by Impairing T Cell Cytotoxicity. Cancer Res (2024)169. Optimized BCMA/CS1 Bispecific TRuC-T cells Secreting IL-7 and CCL21 Robustly Control Multiple Myeloma. Nat Commun (2024)170. AKR1C3 mediates gastric cancer cell invasion and metastasis via the AKT and JNK/p-NF-κB signaling pathways. Scientific Reports (2024)171. AKR1B1 is Required for Maintaining Acute Leukemia Cell Survival by Epigenetic Silencing of Tumor Suppressor Genes. Biochem Genet (2024)172. An antibody cocktail targeting two different CD73 epitopes enhances enzyme inhibition and tumor control. Nat Commun (2024)173. Targeting autophagy in HCC treatment: exploiting the CD147 internalization pathway. Cell Commun Signal (2024)174. Fe3O4 nanoparticles containing gambogic acid inhibit metastasis in colorectal cancer via the RORB/EMILIN1 axis. Cell Adh Migr (2024)175. Palmitoylation of TIM-3 promotes immune exhaustion and restrains antitumor immunity. Sci Immunol (2024)176. RERE-AS1 enhances the effect of CDK4/6 inhibitor Ribociclib and suppresses malignant phenotype in breast cancer via MEK/ERK pathway. J Transl Med (2024)177. TSG101 depletion dysregulates mitochondria and PML NBs, triggering MAD2-overexpressing interphase cell death (MOID) through AIFM1-PML-DAXX pathway. Cell Death Dis (2024)178. Isolation and identification of patient-derived liver cancer stem cells and development of personalized treatment strategies. J Transl Med (2024)179. Ectopic expression of NKG7 enhances CAR-T function and improves the therapeutic efficacy in liquid and solid tumors. Pharmacol Res (2024)180. PCYT2 inhibits epithelial-to-mesenchymal transition in colorectal cancer by elevating YAP1 phosphorylation. JCI Insight (2024)181. TCR-mimicking STAR conveys superior sensitivity over CAR in targeting tumors with low-density neoantigens. Cell Rep (2024)182. Sustained Endocytosis Inhibition via Locally‐Injected Drug‐Eluting Hydrogel Improves ADCC‐Mediated Antibody Therapy in Colorectal Cancer. Adv Sci (Weinh) (2024)183. Efficacy and safety of novel multiple-chain DAP-CAR-T cells targeting mesothelin in ovarian cancer and mesothelioma: a single-arm, open-label and first-in …. Genome Med (2024)184. Chimeric cytokine receptor TGF-β RⅡ/IL-21R improves CAR-NK cell function by reversing the immunosuppressive tumor microenvironment of gastric cancer. Pharmacological research (2025)185. NIPAL1 as a prognostic biomarker associated with pancreatic adenocarcinoma progression and immune infiltration. BMC cancer (2025)186. Airway Basal Stem Cells Inflammatory Alterations in COVID‐19 and Mitigation by Mesenchymal Stem Cells. Cell proliferation (2025)187. Upregulation of CD19 by low‐dose chidamide promotes CAR T cells functionality in B-cell non-Hodgkin lymphoma. Discover oncology (2025)188. GITRL enhances cytotoxicity and persistence of CAR-T cells in cancer therapy. Molecular therapy (2025)189. ROR1 CAR-T cells and ferroptosis inducers orchestrate tumor ferroptosis via PC-PUFA2. Biomarker research (2025)190. SLC1A4 Promotes Malignant Transformation of Hepatocellular Carcinoma by Activating the AKT Signaling. Analytical cellular pathology (Amsterdam) (2025)191. Combined anti-leukemic effect of gilteritinib and GSK-J4 in FLT3-ITD+ acute myeloid leukemia. Translational oncology (2025)192. CPSF6-RARγ interacts with histone deacetylase 3 to promote myeloid transformation in RARG-fusion acute myeloid leukemia. Nature communications (2025)193. Targeting on the PI3K/mTOR: a potential treatment strategy for clear cell ovarian carcinoma. (2025)194. Metabolic‐Immune Suppression Mediated by the SIRT1‐CX3CL1 Axis Induces Functional Enhancement of Regulatory T Cells in Colorectal Carcinoma. Advanced science (Weinheim, Baden-Wurttemberg, Germany) (2025)195. CD70-targeted iPSC-derived CAR-NK cells display potent function against tumors and alloreactive T cells. Cell reports (2025)196. Inhibition of AXL ameliorates pulmonary fibrosis via attenuation of M2 macrophage polarization. The European respiratory journal (2025)197. Defining ortholog-specific UHRF1 inhibition by STELLA for cancer therapy. Nature communications (2025)198. NPC1 controls TGFBR1 stability in a cholesterol transport-independent manner and promotes hepatocellular carcinoma progression. Nature communications (2025)199. Triptolide alleviates allergic airway inflammation by inhibiting group 2 innate lymphoid cell function. International immunopharmacology (2025)200. Intratumoral Stenotrophomonas Maltophilia in Breast Cancer: Unraveling the Interplay with Hormone Receptors and Impact on Tumor Immunity. International journal of biological sciences (2025)201. ARF3 as a novel biomarker and target in acute myeloid leukemia: Insights from pan-cancer analysis. Genomics (2025)202. LGR4 promotes proliferation and homing via activation of the NF-κB signaling pathway in multiple myeloma. International journal of oncology (2025)203. Identification of human cranio-maxillofacial skeletal stem cells for mandibular development. Science advances (2025)204. Improved Efficacy of Triple‐Negative Breast Cancer Immunotherapy via Hydrogel‐Based Co‐Delivery of CAR‐T Cells and Mitophagy Agonist. Advanced science (Weinheim, Baden-Wurttemberg, Germany) (2025)205. Targeting EGFR-binding protein SLC7A11 enhancing antitumor immunity of T cells via inducing MHC-I antigen presentation in nasopharyngeal carcinoma. Cell death & disease (2025)206. The XIAP inhibitor AZD5582 improves the treatment effect of microwave ablation on hepatocellular carcinoma. Frontiers in immunology (2025)207. Betaine inhibits the stem cell-like properties of hepatocellular carcinoma by activating autophagy via SAM/m6A/YTHDF1-mediated enhancement on ATG3 stability. Theranostics (2025)208. Manganese-Loaded pH-Responsive DNA Hydrogels Enable Tg-Guided Thyroid Tumor Targeted Magnetic Resonance Imaging. ACS applied materials & interfaces (2025)209. Genome-wide CRISPR screening identifies PHF8 as an effective therapeutic target for KRAS- or BRAF-mutant colorectal cancers. Journal of experimental & clinical cancer research : CR (2025)210. Tumor vascular endothelial cells promote immune escape by upregulating PD-L1 expression via crosstalk between NF-κB and STAT3 signaling pathways in nasopharyngeal carcinoma. Cell death & disease (2025)211. SHR-1916: A Novel PEGylated Interleukin-2 Analogue with Altered Cellular Selectivity and Improved Pharmacokinetic Profiles for Cancer Immunotherapy. Drug design, development and therapy (2025)212. STX17-DT facilitates axitinib resistance in renal cell carcinoma by inhibiting mitochondrial ROS accumulation and ferroptosis. Cell death & disease (2025)213. Targeted delivery of CCL3 reprograms macrophage antigen presentation and enhances the efficacy of immune checkpoint blockade therapy in hepatocellular carcinoma. Journal for immunotherapy of cancer (2025)214. Enhanced efficacy of immune checkpoint inhibitors by folate-targeted multifunctional drug through synergistic therapy inducing ferroptosis and immunogenic cell death in bladder cancer. Materials today. Bio (2025)215. Targeting platinum-resistant ovarian cancer by disrupting histone and RAD51 lactylation. Theranostics (2025)216. KRASG12D-driven pentose phosphate pathway remodeling imparts a targetable vulnerability synergizing with MRTX1133 for durable remissions in PDAC. Cell reports. Medicine (2025)